Health

FDA Approves Zusduri (mitomycin) for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

DailyTrendDailyTrend
Jun 13, 2025 - 15:00
 0  0
FDA Approves Zusduri (mitomycin) for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--Jun. 12, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the U.S. Food and...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

Congo Has Astronomical Rates of Sexual Violence. Now Vi...

DailyTrend Aug 22, 2025  0  0

Trump’s Get-Tough Approach on Homelessness May Sweep Up Veterans

Trump’s Get-Tough Approach on Homelessness May Sweep Up...

DailyTrend Aug 19, 2025  0  0

FDA Approves Tonmya (cyclobenzaprine hydrochloride sublingual tablets) for the Treatment of Fibromyalgia

FDA Approves Tonmya (cyclobenzaprine hydrochloride subl...

DailyTrend Aug 16, 2025  0  0

Are Marathons and Extreme Running Linked to Colon Cancer?

Are Marathons and Extreme Running Linked to Colon Cancer?

DailyTrend Aug 20, 2025  0  0

Why Wildfire Fighters Are Getting Dangerously Sick

Why Wildfire Fighters Are Getting Dangerously Sick

DailyTrend Aug 17, 2025  0  0

Wegovy Granted Accelerated Approval in the US for the Treatment of MASH

Wegovy Granted Accelerated Approval in the US for the T...

DailyTrend Aug 18, 2025  0  0